RCS - Hemogenyx Pharma Plc - Macrophage-Directed Therapies Summit Presentation

Hemogenyx PharmaceuticalsAnnouncement

29/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240729:nRSc8674Xa&default-theme=true

RNS Number : 8674X  Hemogenyx Pharmaceuticals PLC  29 July 2024

 

29 July 2024

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Presentation at Macrophage-Directed Therapies Summit

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical-stage
biopharmaceutical group developing treatments for cancers and viral diseases,
is pleased to announce its participation in the 6th Macrophage-Directed
Therapies Summit ("Summit"), which will be held on October 1-3, 2024, in
Boston, MA. The Company will present its work on its proprietary Chimeric Bait
Receptor ("CBR") platform.

 

The Company's CBR platform is an advanced immunotherapy designed to program or
redirect innate immune cells, such as macrophages, to eliminate specific types
of cancer as well as combat infections from both existing and emerging viral
threats. The Company's presentation at the Summit will focus on the use of the
CBR platform for the treatment of rare cancers.

 

Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals,
commented: "Our presentation at the Summit will provide the Company with an
opportunity to further establish its unique position in the emerging field of
myeloid cell therapies. It will also allow us to exchange ideas with
like-minded cell therapy developers, potential collaborators, and investors."

 

 

Enquiries:

 

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)

 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl

 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

About Hemogenyx Pharmaceuticals plc

 

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility.

The Company is a clinical-stage biopharmaceutical group developing new
medicines and treatments for life-threatening diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as a platform technology that it uses as an engine for
novel product development.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAEXSAAELEFA